
Wogli 0.3mg Tablet MD
Marketer
Lemford Biotech Pvt Ltd
Salt Composition
Voglibose (0.3mg)
Overview Wogli 0.3mg Tablet MD
DiaWog 0.3mg tablets are indicated for managing type 2 diabetes. This medication assists in post-prandial blood glucose regulation, employed when dietary modifications and other comparable therapies prove insufficient. Administer DiaWog 0.3mg immediately prior to meals; dosage and frequency are to be determined by your physician for optimal glycemic control. Discontinue use only under medical supervision; abrupt cessation may elevate blood glucose, potentially causing serious complications such as renal impairment or vision loss. DiaWog 0.3mg is a component of a comprehensive diabetes management plan encompassing a balanced diet, regular physical activity, and weight management as directed by your doctor. Regular blood glucose monitoring is crucial during treatment. Commonly reported adverse effects include intestinal gas, abdominal discomfort, appetite suppression, constipation, and diarrhea. Report any persistent or bothersome side effects to your physician. While DiaWog 0.3mg alone does not induce hypoglycemia, concomitant use with other antidiabetic agents (particularly insulin or sulfonylureas) may increase this risk. Treat hypoglycemic episodes with plain glucose; sucrose is ineffective in this context. Inform your doctor of any pre-existing hepatic or renal conditions before commencing treatment. Contraindicated in patients with bowel inflammation or ulceration (e.g., Crohn's disease or ulcerative colitis). Pregnant or lactating individuals should seek medical counsel prior to initiating therapy. Disclose all current medications to ensure safe concurrent use. Limit alcohol consumption as it can heighten the risk of hypoglycemia.
Uses of Wogli 0.3mg Tablet MD
Managing type 2 diabetes
Major Benefits of Wogli 0.3mg Tablet MD:
Administer this medication precisely as your physician directs, adhering to both dosage and treatment length. Avoid handling the tablets with damp hands. Place the tablet in your mouth, but refrain from swallowing immediately. Consume the Wogli 0.3mg Tablet MD on an empty stomach.
Common Side effects of Wogli 0.3mg Tablet MD:
- Skin rash
- Flatulence
- Abdominal pain
- Diarrhea
How to use Wogli 0.3mg Tablet MD:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Avoid handling the tablets with damp hands. Place the tablet in your mouth, but refrain from swallowing immediately. Wogli 0.3mg Tablet MD should be ingested on an empty stomach.
How Wogli 0.3mg Tablet MD works:
Wogli 0.3mg Tablet MD is an antidiabetic medication that works by blocking the action of intestinal enzymes which digest complex carbohydrates. This action reduces postprandial hyperglycemia.
SAFETY ADVICE
AlcoholUNSAFE
Consuming alcohol while taking Wogli 0.3mg Tablet MD is dangerous.
PregnancySAFE IF PRESCRIBED
Pregnancy use of 0.3mg WogLi tablets (MD) is typically deemed safe. Animal research indicates minimal or absent harm to fetuses, though human data remain scarce.
Breast feedingSAFE IF PRESCRIBED
Employing the 0.3mg Wohgli Tablet MD during lactation is likely safe. Available human data indicates minimal infant risk associated with this medication.
DrivingSAFE
Driving ability is typically unaffected by taking a 0.3mg tablet of Wogli MD.
KidneyCAUTION
Wogli 0.3mg Tablet MD requires careful administration for individuals with advanced kidney impairment. Dosage modification of Wogli 0.3mg Tablet MD might be necessary. Physician consultation is recommended.
LiverCAUTION
Patients with severe hepatic impairment should use Wogli 0.3mg Tablet MD cautiously, as dosage modification may be necessary. Physician consultation is advised.
What if you forget to take Wogli 0.3mg Tablet MD :
Omit any missed dose of Wogli 0.3mg Tablet MD and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Wogli 0.3mg Tablet MD
| Label | Value |
|---|---|
| Chemical Classification | Valiolamine analog |
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
| Action Class | Alpha-glucosidase inhibitors |
